Credit Suisse Group restated their neutral rating on shares of AbbVie Inc. (NYSE:ABBV) in a research note issued to investors on Sunday morning. Credit Suisse Group currently has a $94.00 price objective on the stock, up from their previous price objective of $74.00.

ABBV has been the subject of a number of other research reports. Zacks Investment Research lowered AbbVie from a hold rating to a sell rating in a research note on Tuesday, July 4th. Vetr upgraded AbbVie from a hold rating to a buy rating and set a $76.28 target price for the company in a research note on Wednesday, July 26th. Goldman Sachs Group, Inc. (The) restated a buy rating and issued a $100.00 target price (up previously from $85.00) on shares of AbbVie in a research note on Friday, September 8th. Jefferies Group LLC restated a buy rating and issued a $107.00 target price (up previously from $94.00) on shares of AbbVie in a research note on Friday, September 15th. Finally, BidaskClub upgraded AbbVie from a buy rating to a strong-buy rating in a research note on Wednesday, September 6th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. AbbVie has a consensus rating of Buy and a consensus target price of $89.90.

Shares of AbbVie (NYSE ABBV) opened at 89.90 on Friday. The firm has a 50 day moving average price of $81.10 and a 200-day moving average price of $71.64. AbbVie has a 12-month low of $55.06 and a 12-month high of $90.95. The company has a market cap of $143.31 billion, a price-to-earnings ratio of 22.11 and a beta of 1.51. AbbVie also saw unusually large options trading on Monday. Stock investors purchased 278 put options on the company. This represents an increase of approximately 121% compared to the average daily volume of 126 put options.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 28th. The company reported $1.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.40 by $0.02. The company had revenue of $6.94 billion during the quarter, compared to analyst estimates of $6.93 billion. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The firm’s quarterly revenue was up 7.6% on a year-over-year basis. During the same quarter last year, the business posted $1.26 EPS. On average, equities analysts expect that AbbVie will post $5.52 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Credit Suisse Group Reiterates “Neutral” Rating for AbbVie Inc. (ABBV)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/05/credit-suisse-group-reiterates-neutral-rating-for-abbvie-inc-abbv.html.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be given a dividend of $0.64 per share. This represents a $2.56 dividend on an annualized basis and a dividend yield of 2.85%. The ex-dividend date is Thursday, October 12th. AbbVie’s dividend payout ratio (DPR) is presently 62.90%.

In other news, VP Robert A. Michael sold 6,699 shares of the firm’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $88.00, for a total transaction of $589,512.00. Following the sale, the vice president now directly owns 10,007 shares in the company, valued at approximately $880,616. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of the firm’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $85.02, for a total value of $705,666.00. Following the sale, the senior vice president now owns 93,099 shares in the company, valued at $7,915,276.98. The disclosure for this sale can be found here. Insiders have sold a total of 379,890 shares of company stock worth $27,187,817 over the last 90 days. Insiders own 0.23% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Formidable Asset Management LLC grew its position in shares of AbbVie by 0.3% during the 2nd quarter. Formidable Asset Management LLC now owns 3,926 shares of the company’s stock valued at $285,000 after acquiring an additional 10 shares during the period. WealthTrust Axiom LLC grew its position in shares of AbbVie by 0.3% during the 2nd quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock valued at $312,000 after acquiring an additional 15 shares during the period. Abner Herrman & Brock LLC grew its position in shares of AbbVie by 0.3% during the 2nd quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock valued at $456,000 after acquiring an additional 18 shares during the period. Bollard Group LLC grew its position in shares of AbbVie by 0.5% during the 2nd quarter. Bollard Group LLC now owns 3,764 shares of the company’s stock valued at $273,000 after acquiring an additional 19 shares during the period. Finally, St. Louis Trust Co grew its position in shares of AbbVie by 0.7% during the 2nd quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock valued at $248,000 after acquiring an additional 23 shares during the period. Hedge funds and other institutional investors own 68.26% of the company’s stock.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.